Approximately 30% of patients with epilepsy do not experience full seizure control on their antiseizure drug (ASD) regimen. Historically, screening for novel ASDs has relied on evaluating efficacy following a single administration of a test compound in either acute electrical or chemical seizure induction. However, the use of animal models of spontaneous seizures and repeated administration of test compounds may better differentiate novel compounds. Therefore, this approach has been instituted as part of the National Institute of Neurological Disorders and Stroke Epilepsy Therapy Screening Program screening paradigm for pharmacoresistant epilepsy.

中文翻译：

---

自发性癫痫大鼠亚慢性给药抗癫痫药物的评价

大约 30% 的癫痫患者在其抗癫痫药物 (ASD) 方案中没有完全控制癫痫发作。从历史上看，新型 ASD 的筛选依赖于评估单次给药测试化合物在急性电或化学癫痫诱发中的功效。然而，使用自发性癫痫动物模型和重复给药测试化合物可以更好地区分新化合物。因此，这种方法已被作为国家神经疾病研究所和中风癫痫治疗筛查项目耐药性癫痫筛查范式的一部分。